PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

Food and Healthcare Press Releases Thursday February 15, 2018 10:19
MADRID--15 Feb--PRNewswire-FirstCall/InfoQuest

PharmaMar (MCE: PHM) has announced today the   signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the development, manufacture and commercialization of antibody-drug conjugates (ADCs) and/or other drug conjugates incorporating PharmaMar payloads.

(Logo: http://mma.prnewswire.com/media/624563/PharmaMar_Logo.jpg )

According to the terms of the agreement, PharmaMar receives an upfront payment of 5,000,000 US dollars on signing, followed by development milestones if a product enters clinical development conducted by Seattle Genetics. In addition, PharmaMar is eligible for potential approval and sales milestones as well as royalties, once a product receives regulatory approval and is commercialized.

PharmaMar has a Marine Payloads unit. These are new, structurally diverse molecules with novel mechanisms of action that provide a unique opportunity to develop next generation ADCs. These payloads are highly potent, with sub-nanomolar cytotoxic activity. ADCs are targeted cancer treatments designed to harness the specificity of antibodies to deliver cell-killing agents directly to cancer cells.

As Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, stated, "We are glad to sign this license agreement with Seattle Genetics, a pioneer and leading company in the ADC market, because it allows us to work together in these cutting-edge cancer treatments."

The payloads department at PharmaMar is new, placing the company as a supplier of cytotoxic products, necessary for all companies working within the field of ADCs.
About Seattle Genetics Inc.

Seattle Genetics Inc is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. Seattle Genetics is headquartered in Bothell, Washington (US)http://www.seattlegenetics.com.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS(R) in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, lurbinectedin, plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, To learn more about PharmaMar, please visit us at http://www.pharmamar.com .

Contact details: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500).
Source: PharmaMar

Latest Press Release

Venus Medtech Launches Global Advisory Board to Target for International Market

Venus Medtech (Hangzhou) Inc., a Chinese medical device company specializing in transcatheter valve replacement therapy, has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board. The Board...

Future Health Index, Commissioned by Philips, Identifies Key Recommendations for Better Health Information Exchange to Drive Value in Healthcare

Royal Philips (NYSE: PHG) (AEX: PHIA), a global leader in health technology, today released a new Future Health Index (FHI) report " Moving data to the heart of health systems: Increasing vital technology adoption to make value-based healthcare a reality...

PULSUS Group collaborates with Anbu Kochi to Contribute towards Kerala Flood Victims

In a humanitarian effort, PULSUS Group - in collaboration with Anbu Kochi - is responding to the calamity of the recent, unprecedented floods in the Indian state of Kerala by providing contributions to aid relief and rehabilitation measures. PULSUS Group...

Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular...

Experts Call for Improved Identification of #High Burden# Rosacea Patients in Everyday Practice

- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea alone Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report...

Related Topics